Compare Nerdwallet Inc (NRDS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Sanofi SA — how do they compare? Nerdwallet Inc trades at $9.81 (market cap $625.17M), while Sanofi SA trades at $40.17 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 152.2× Nerdwallet Inc's market cap, and Sanofi SA pays a 6.01% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Sanofi SA for 94 Days on average.
| NRDS | SNY | |
|---|---|---|
Market Cap | $625.17M | $95.18B |
Volume | 1,321,316 | 2,995,646 |
Sector | Media | Health |
52-Week High | $15.93 | $52.34 |
52-Week Low | $7.58 | $39.51 |
Typical Hold Time | 45 Days | 94 Days |
Enterprise Value | $539.47M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $10.03, up 10.4% in the last session, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with improving fundamentals - revenue grew from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent news highlights the company's Financial Resilience Index publications and Q2 2026 results showing 6% revenue growth despite search pressure in some product categories.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key risks include organic search volatility and competitive pressures, but strong cash flow generation and attractive valuation multiples (P/E 10.87, P/S 0.81) support the bullish case for long-term investors.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
